



# sensei<sup>TM</sup> BIO

## **Sensei Biotherapeutics to Participate in the 13th Annual Jefferies Global Healthcare Conference**

November 2, 2022

BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer, today announced that John Celebi, President and Chief Executive Officer, will present at the 13th Annual Jefferies Global Healthcare Conference, being held in London, United Kingdom, on Thursday, November 17, 2022, at 7:25 a.m. GMT.

A webcast of Sensei's presentation will be available in the [Investors](#) section of the Sensei website. A replay of the webcast will be on the website for approximately 90 days following the event. Registration for the live webcast is available [here](#).

### **About Sensei Biotherapeutics**

Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb<sup>TM</sup> (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable checkpoints and other immunosuppressive signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei's lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. For more information, please visit [www.senseibio.com](http://www.senseibio.com), and follow the company on Twitter @SenseiBio and [LinkedIn](#).

### **Investor Contact:**

Michael Biega  
Senior Director, Investor Relations  
Sensei Biotherapeutics  
[mbiega@senseibio.com](mailto:mbiega@senseibio.com)

### **Media Contact:**

Chris Railey  
Ten Bridge Communications  
[chris@tenbridgecommunications.com](mailto:chris@tenbridgecommunications.com)